CD163+ Immune Cells and Metastatic Breast Cancer Prognosis
Author Information
Author(s): Lindberg Ida, Saleh Aya, Tutzauer Julia, Gunnarsdottir Frida Björk, Rydén Lisa
Primary Institution: Lund University
Hypothesis
The study aims to determine the levels of CD163+ immune cells in patients with metastatic breast cancer and their association with clinical outcomes.
Conclusion
High levels of CD163+ immune cells in primary tumors are associated with worse prognosis in metastatic breast cancer patients.
Supporting Evidence
- High levels of CD163+ immune cells in primary tumors are linked to shorter progression-free survival.
- Patients with high CD163+ immune cells had a median overall survival of 17.8 months compared to 38.6 months for those with low levels.
- The study included 139 patients with newly diagnosed metastatic breast cancer.
Takeaway
This study found that patients with more CD163+ immune cells in their primary tumors might not do as well as those with fewer, which could help doctors predict how patients will respond to treatment.
Methodology
The study used immunohistochemistry and gene expression analyses to evaluate CD163+ immune cell levels in primary tumors, lymph node metastases, and distant metastases.
Potential Biases
Potential biases may arise from the observational design and the specific patient cohort used.
Limitations
The study's exploratory nature and relatively small cohort size limit the generalizability of the findings.
Participant Demographics
The median age at metastatic breast cancer diagnosis was 65 years, with a majority having ER-positive disease.
Statistical Information
P-Value
0.006
Confidence Interval
17.8 months (11.4–24.1) vs 38.6 months (28.5–48.8)
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website